1. Home
  2. ASPI vs PRME Comparison

ASPI vs PRME Comparison

Compare ASPI & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ASP Isotopes Inc.

ASPI

ASP Isotopes Inc.

N/A

Current Price

$4.28

Market Cap

475.3M

Sector

Industrials

ML Signal

N/A

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

N/A

Current Price

$3.17

Market Cap

536.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASPI
PRME
Founded
2021
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
475.3M
536.4M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
ASPI
PRME
Price
$4.28
$3.17
Analyst Decision
Strong Buy
Buy
Analyst Count
2
6
Target Price
$12.00
$7.56
AVG Volume (30 Days)
3.9M
2.7M
Earning Date
04-10-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.18
EPS
N/A
N/A
Revenue
$23,849,000.00
$4,632,000.00
Revenue This Year
$68.41
$7.06
Revenue Next Year
$126.69
$47.01
P/E Ratio
N/A
N/A
Revenue Growth
475.48
55.28
52 Week Low
$3.51
$2.67
52 Week High
$14.49
$6.94

Technical Indicators

Market Signals
Indicator
ASPI
PRME
Relative Strength Index (RSI) 47.35 49.07
Support Level $3.98 $2.73
Resistance Level $5.88 $3.60
Average True Range (ATR) 0.28 0.19
MACD 0.12 0.03
Stochastic Oscillator 85.79 72.27

Price Performance

Historical Comparison
ASPI
PRME

About ASPI ASP Isotopes Inc.

ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: